ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0915

MTORC1/STAT1 Signaling Stimulates CFB Expression and Alternative Complement Pathway Activation to Induce Podocyte Dysfunction and Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic


  • Lu, Qingmiao, Nanjing Medical University, Nanjing, Jiangsu, China
  • Dai, Chunsunb, Nanjing Medical University, Nanjing, Jiangsu, China

Alternative complement pathway activation has been reported in diabetic kidney disease (DKD). However, the role and mechanisms for regulating alternative complement pathway activation in podocyte dysfunction and DKD are not understood.


STZ-induced DKD mice, db/db mice, Podocyte-specific TSC1 deletion mice were used.


The analysis of GSE30528 data and the immunohistochemical staining results showed that mTORC1 signaling, STAT1, complement factor B (CFB) and complement alternative pathway were activated in podocytes from patients and animal models with DKD. Knocking down CFB remarkably alleviated podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in DKD mice. In addition, ablation of Tsc1 in podocytes led to mTORC1 and STAT1 signaling activation, CFB induction, and alternative complement pathway activation in the glomeruli. In cultured podocytes, high glucose culture could activate mTORC1 signaling, stimulate STAT1 phosphorylation and upregulate CFB expression. Blockade of mTORC1 or STAT1 signaling could abolish high glucose upregulated CFB expression in podocytes.


This study uncovers that mTORC1/STAT1 activation in podocytes may promote DKD progression through activating complement alternative pathway.


  • Government Support - Non-U.S.